Edition:
India

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

49.67USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$49.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
136,191
52-wk High
$56.10
52-wk Low
$22.23

Latest Key Developments (Source: Significant Developments)

Crispr Therapeutics Posts Q2 Loss Per Share Of $1.01
Tuesday, 30 Jul 2019 

July 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - ENROLLING IN PHASE 1/2 CLINICAL TRIAL OF CTX110™, TARGETING CD19+ MALIGNANCIES.QTRLY LOSS PER SHARE $1.01.ENROLLMENT IN BOTH PHASE 1/2 STUDIES OF CTX001 IN PATIENTS WITH TDT AND IN PATIENTS WITH SEVERE SCD IS ONGOING.EXPECTS TO OBTAIN PRELIMINARY SAFETY AND EFFICACY DATA IN LATE 2019 FROM PHASE 1/2 STUDIES OF CTX001.  Full Article

Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia
Tuesday, 16 Apr 2019 

April 16 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA.  Full Article

Crispr Therapeutics Q4 Net Loss Was $47.6 Million
Monday, 25 Feb 2019 

Feb 25 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - ON TRACK TO INITIATE CLINICAL TRIAL FOR CTX110, TARGETING CD19+ MALIGNANCIES, IN 1H 2019.CRISPR THERAPEUTICS AG - $456.6 MILLION IN CASH AS OF DECEMBER 31, 2018.CRISPR THERAPEUTICS AG - TOTAL COLLABORATION REVENUE WAS $0.1 MILLION FOR Q4 OF 2018 COMPARED TO $32.3 MILLION FOR Q4 OF 2017.CRISPR THERAPEUTICS AG - NET LOSS WAS $47.6 MILLION FOR Q4 OF 2018 COMPARED TO INCOME OF $0.1 MILLION FOR Q4 OF 2017.  Full Article

Vertex Pharmaceuticals (Europe) Reports Open Market Buy Of 90,742 Shares Of CRISPR Therapeutics At Prices Ranging From $22.58/Share To $24.97/Share
Thursday, 27 Dec 2018 

Dec 26 (Reuters) - CRISPR Therapeutics AG ::VERTEX PHARMACEUTICALS (EUROPE) REPORTS OPEN MARKET BUY OF 90,742 SHARES OF CRISPR THERAPEUTICS AT PRICES RANGING FROM $22.58/SHARE TO $24.97/SHARE.  Full Article

Crispr Therapeutics Announces Pricing of 4.21 Million Shares
Friday, 21 Sep 2018 

Sept 20 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 4.21 MILLION COMMON SHARES PRICED AT $47.50PER SHARE.  Full Article

CRISPR And Vertex Provide Update On FDA Review Of Investigational NDA
Thursday, 31 May 2018 

May 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND VERTEX PROVIDE UPDATE ON FDA REVIEW OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 FOR THE TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS-PLANNED INITIATION OF PHASE 1/2 TRIAL OF CTX001 IN EUROPE IN ADULT PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA IS UNCHANGED.CRISPR THERAPEUTICS AG - U.S FDA HAS PLACED A CLINICAL HOLD ON IND FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS AG - COMPANIES EXPECT TO INITIATE PHASE 1/2 TRIAL OF CTX001 IN SECOND HALF OF 2018.  Full Article

Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
Friday, 5 Jan 2018 

Jan 4 (Reuters) - Crispr Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $22.75PER SHARE.  Full Article

Crispr Therapeutics ‍Commences Public Offering Of $100 Mln Common Shares​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.CRISPR THERAPEUTICS AG - ‍COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON SHARES​.  Full Article

Crispr Therapeutics Announces Appointment Of Dr. Rodger Novak As Chairman Of The Board
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. RODGER NOVAK AS CHAIRMAN OF THE BOARD.CRISPR THERAPEUTICS AG - ‍RODGER NOVAK WILL SUCCEED TONY COLES​.CRISPR THERAPEUTICS AG - ‍TONY COLES WILL REMAIN A SENIOR ADVISOR TO CRISPR THERAPEUTICS​.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article